Hepatitis web study H EPATITIS W EB S TUDY Christian B. Ramers, MD, MPH Assistant Medical Director,...
-
Upload
adrian-james -
Category
Documents
-
view
216 -
download
0
Transcript of Hepatitis web study H EPATITIS W EB S TUDY Christian B. Ramers, MD, MPH Assistant Medical Director,...
Hepatitisweb study
HEPATITIS WEB STUDY
Christian B. Ramers, MD, MPHAssistant Medical Director, Family Health Centers of San DiegoHIV/HCV Distance Education Specialist, Northwest AETCUniversity of Washington School of Medicine
Hepatitis C Testing Recommendations
Last Updated: February 28, 2013
Hepatitisweb study
Disclosure Information
• Speaker’s Bureau and Consultant: Gilead Sciences
Hepatitisweb study
Hepatitisweb study
CDC HCV Testing Recommendation
Rationale for Birth Cohort HCV Testing Recommendations
Goals and Potential Impact of HCV Birth Cohort Testing
Hepatitis C Testing Recommendations in the U.S.
Hepatitisweb study
Hepatitisweb study
CDC HCV Testing Recommendations
Hepatitisweb study
1998 – CDC Risk-Based HCV Screening Recommendations
Source: CDC and Prevention.
• Persons who ever injected illegal drugs
• Persons with selected medical conditions, including- receipt of clotting factor concentrates produced before 1987;- ever on chronic (long-term) hemodialysis; and- persistently abnormal alanine aminotransferase levels
• Prior recipients of transfusions or organ transplants (before July 1992)
HCV screening based on risk for infection:
• Healthcare, emergency medical, and public safety workers after needle sticks, sharps, or mucosal exposures to HCV-positive blood
• Children born to HCV-positive women
HCV screening based on recognized exposure:
Hepatitisweb study
Hepatitisweb studySource: CDC and Prevention. MMWR. 2012:RR61:1-32.
Hepatitisweb study
2012 CDC Birth Cohort HCV Testing Recommendations
In addition to testing adults of all ages at risk for hepatitis C virus:
Adults born during 1945 to 1965 should receive 1-time testing for HCV
without prior ascertainment of HCV risk.
All persons identified with HCV infection should receive:
- A brief alcohol screening and intervention as clinically indicated,
- Referral to appropriate care and treatment services for HCV infection,
- Post-test counseling
Source: Source: CDC and Prevention. MMWR. 2012:RR61:1-32.
Hepatitisweb study
Hepatitis C Testing Methods
YY Y• Screening: Hepatitis C Antibody Testing
- Highly sensitive and specific
- Reactive test indicates current or resolved infection
• Supplemental: Nucleic Acid Testing
- Quantitative and qualitative HCV RNA tests used
- Positive test indicates active infection
Hepatitisweb study
Hepatitisweb study
Rationale for Birth Cohort HCV Testing Recommendations
Hepatitisweb study
1968 World Health Organization GuidelinesCriteria for New Screening Programs
When considering general public health screening programs, the following factors should be considered:
Relevance: Is the condition an important public health problem with a well-understood natural history and a latent phase?
Feasibility: Is there an effective intervention? Is a screening test available, easy to use, accurate, and acceptable to the population?
Effectiveness: Does early diagnosis and treatment affect outcomes?
Cost Effectiveness: Is the cost of the screening program worth the investment in terms of health benefit gained?
Adapted from: Wilson JMG and Jungner G. Principles and Practice of Screening for Disease. WHO. 1968.
Hepatitisweb study
Sources: Armstrong GL, et al. Ann Intern Med. 2006;144:705-14. Chak E, et al. Liver Int. 2011;31:1090-101.
Estimated Prevalence of Chronic Active Hepatitis C in U.S.
3.2 - 4.1 Million Persons Living with Chronic HCV
Hepatitisweb studySource: Ly KN, et al. Ann Intern Med. 2012:156:271-8.
Age-Adjusted Mortality Rates from HBV, HCV, & HIV United States, 1999-2007
Rate
per
100,0
00 P
Y
Year
HIV
1999 2000 2001 2002 2003 2004 2006 20072005
5
4
3
2
1
0
7
6
Hepatitis C
Hepatitis B
Hepatitisweb studySource: Rein DR, et al. Dig Liver Dis. 2011:43:66-72.
Forecasted 2010-2060 Annual HCV-Related Deaths in the United States
Persons with Chronic Hepatitis C and no Cirrhosis in 2005N
um
ber
Year
2010
Deaths
2014 2018 2022 2026 2030 2034 2038 2042 2046 2050 2054 2058
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
0
45,000
Hepatitisweb studySource: Rein DR, et al. Dig Liver Dis. 2011:43:66-72.
Forecasted 2010-2060 Annual HCV-Related Deaths in the United States
Persons with Chronic Hepatitis C and no Cirrhosis in 2005N
um
ber
Year
2010
Deaths
2014 2018 2022 2026 2030 2034 2038 2042 2046 2050 2054 2058
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
0
45,000Peak
Hepatitisweb studySource: Rein DR, et al. Dig Liver Dis. 2011:43:66-72.
Forecasted 2010-2060 Annual HCV-Related Deaths in the United States
Persons with Chronic Hepatitis C and no Cirrhosis in 2005N
um
ber
Year
2010
Deaths
2014 2018 2022 2026 2030 2034 2038 2042 2046 2050 2054 2058
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
0
45,000
Without treatment an estimated 1,071,229 persons will have died from hepatitis C by 2060
Hepatitisweb studySource: Denniston M, et al. Hepatology. 2012:55:1652-61.
NHANES Survey, United States, 2001-2008Awareness of HCV Infection Status
Unaware of HIV infection
21%
Knowledge of HCV Infection
Aware50%
Unware 50%
Chart Title
Hepatitisweb study
Source: WHO Hepatitis C Fact Sheet http://www.who.int/immunization/topics/hepatitis_c/en/index.html
Burden of disease related to HCV
Outcome Key Facts
Cirrhosis• Develops in 20% of those who are chronically
infected with HCV over 20-30 years
Decompensated Cirrhosis• High risk of mortality from ruptured esophageal
varices, bacterial peritonitis, hepatorenal syndrome/renal failure, encephalopathy
Hepatocellular Carcinoma • Fastest growing Cancer in the US • 76% associated with chronic HCV infection• 4% annual incidence in those with cirrhosis
Liver Transplantation • HCV responsible for 65% of liver transplants
worldwide
HCV Mortality• Estimated at 16,000/year• Likely to peak ~2030
Burden of Liver disease expected to triple in next 10-20 yrs
Hepatitisweb study
Therapy for Hepatitis C: Historical Milestones
0
20
40
60
80
100
6
16
34
42 39
55
70
Su
sta
ine
d V
iro
log
ic R
es
po
ns
e (
%)
1986 1998 2001 2002
Timeline
2011
Hepatitisweb study
Therapy for Hepatitis CProjected SVR Rates with Multiple DAAs
0
20
40
60
80
100
6
16
3442 39
55
70
90
Su
sta
ine
d V
iro
log
ic R
es
po
ns
e (
%)
1986 1998 2001 2002
Timeline
2011 2014
Hepatitisweb studySource: Armstrong GL, et al. Ann Intern Med. 2006;144:705-14.
NHANES Survey: United States, 1988-1994 and 1999-2002
Prevalence of HCV Antibody, by Year of Birth
Year of Birth
HC
V P
revale
nce(%
)
1910
1988–1994 1999–20027.0
6.0
5.0
4.0
3.0
2.0
1.0
01920 1930 1940 1950 1960 1970 1980 1990
Hepatitisweb studySource: Armstrong GL, et al. Ann Intern Med. 2006;144:705-14.
NHANES Survey: United States, 1988-1994 and 1999-2002
Prevalence of HCV Antibody, by Year of Birth
Year of Birth
HC
V P
revale
nce(%
)
1910
1988–1994 1999–20027.0
6.0
5.0
4.0
3.0
2.0
1.0
01920 1930 1940 1950 1960 1970 1980 1990
1945-1965
Hepatitisweb study
Rationale for One-Time HCV Testing of All Persons Born in United States during 1945 to 1965
• Hepatitis C is a major current & future health problem in United States
• Testing can identify persons before onset of severe HCV-related disease
• Hepatitis C infection can be cured with treatment
• Bulk of HCV problem in United States involves persons born 1945-1965
• Approximately 50% of persons with HCV remain unaware of HCV status
Hepatitisweb study
Hepatitisweb study
Goals and Projected Impact of Birth-Cohort Screening
Hepatitisweb study
Goals for Birth Cohort Hepatitis C Testing in U.S.
Improve Survival &
Quality of Life
Prevent New HCV Infections
HCVTesting
HCVDiagnosis
Treat HCVLink to Care
for HCV
Hepatitisweb study
Goals for Birth Cohort Hepatitis C Testing in U.S.
Improve Survival &
Quality of Life
Prevent New HCV Infections
HCVTesting
HCVDiagnosis
Link to Carefor HCV
Hepatitisweb study
HCV Testing of Persons in 1945-1965 Birth Cohort CDC Recommendations for Post Test Counseling
• Refer or obtain advice for care of HCV - experienced primary care provider or specialist
• Educate patient on how to protect liver from further harm- Immunization against Hepatitis A and B- Brief alcohol screening and intervention- Limit exposure to hepatotoxic drugs (e.g. acetaminophen)
• Counsel obese patients on diet & weight Loss- Especially BMI ≥25kg/m2
• Advise on decreasing risk of transmission to others- Donation of blood, tissue, semen- Use of razors, toothbrushes, nail clippers
Source: CDC and Prevention. MMWR. 2012:61(RR-4):1-32.
Hepatitisweb study
HCV Testing of Persons Born 1945-1965Projected Benefit of One Time Birth Cohort Testing
Clinical Outcomes Associated with Risk Based versus Birth Cohort HCV Testing
Source: Rein DB, et al. Ann Intern Med. 2012:156:263-70.
0
200000
400000
600000
800000
1000000
1200000
994,291
360,388
230,784
75,752
591,172
791,053
286,699
183,595
60,268
470,879
Risk-Based Testing + PR
Birth-Cohort Screening + PR and DAA
Pers
on
s
Hepatitisweb study
HCV Testing of Persons Born 1945-1965Projected Benefit of One Time Birth Cohort Testing
Cases Averted with Birth Cohort HCV Testing versus Risk Based HCV Testing
Source: Rein DB, et al. Ann Intern Med. 2012:156:263-70.
-250000
-200000
-150000
-100000
-50000
0
-203,238
-73,689
-47,189
-15,484
-120,879Dif
fere
nce
Hepatitisweb studySource: Rein, DB et al Ann Intern Med 2012:156:263-70.
HCV Testing of Persons Born 1945-1965Cost Effectiveness Compared with other Screening Tests
Breast CA Screening (> age 40)
HIV Screening (age 13-64)
HCV Screen (1945-65) + PEG-IFN/RIB/DAA
HTN Screening (> age 18)
HCV Screen (1945-65) + PEG-IFN/RIB
Colorectal CA (> age 50)
0 10000 20000 30000 40000 50000 60000
49,000
38,000
35,700
30,000
15,700
11,000
Cost per QALY ($)
Hepatitisweb study
Hepatitisweb study
Perform one-time HCV testing of all persons born 1945-1965
Continue risk-based HCV screening
Sound rationale exists for birth-cohort screening
Potential for large impact of birth-cohort testing
CDC Birth Cohort HCV Testing Recommendations in U.S. :
Summary
Hepatitisweb study
Hepatitisweb study
End
This presentation is brought to you byHepatitis Web Study & the Hepatitis C Online Course
Funded by a grant from the Centers for Disease Control and Prevention